Tag: RISE3
-

FDA Pauses Opakalim Enrollment Days After SK Biopharmaceuticals Deal
The FDA paused new enrollment in Biohaven’s opakalim program, adding regulatory uncertainty to SK Biopharmaceuticals’ $795 million epilepsy licensing deal.

The FDA paused new enrollment in Biohaven’s opakalim program, adding regulatory uncertainty to SK Biopharmaceuticals’ $795 million epilepsy licensing deal.